Xenix Medical receives FDA clearance for spinal fixation system, begins full commercial rollout

Xenix Medical has received U.S. Food and Drug Administration 510(k) clearance for its Riva Posterior Fixation System and completed the product's alpha launch, paving the way for full commercial availability, the company announced.

The spinal fixation system is designed to provide surgeons with a modular platform that can be customized for a wide range of patient anatomies and surgical procedures, including complex deformity and revision cases.

According to Xenix, the system features a modular head design that allows surgeons to attach and remove the tulip head from the screw shank using a single-step mechanism. The company said the design provides both audible and tactile confirmation when the components are securely connected.

The company said the tulip-to-shank interface was engineered and tested to provide strength comparable to leading pre-assembled pedicle screw systems while maintaining the flexibility of a modular platform.

Andrew Park, a partner at Texas Spine Consultants in Dallas, said the system's range of screw heads and shanks gives surgeons greater flexibility in creating patient-specific constructs.

"There are other modular systems on the market, but none give me the freedom to create my ideal construct for each patient like Riva," Park said in a statement.

The Riva system includes multiple tulip head and screw shank configurations designed to accommodate varying anatomical requirements and complex surgical constructs. Xenix said the platform is intended to reduce the need for separate implant systems by providing a broader range of options within a single system.

The company said it has incorporated feedback gathered during the alpha launch into its commercial rollout strategy and is expanding distribution and surgeon access across the United States.

Xenix also announced plans to expand the platform's capabilities. Future developments include integrating the company's NanoACTIV surface technology, adding sacropelvic fixation and attachment options for complex deformity procedures, and extending the system for use in minimally invasive surgery.

Ryan Phillips, president of Xenix Medical, said the launch represents a milestone in the company's broader growth strategy.

"Riva's full commercial launch is a significant milestone, but it is just the next step in our accelerating trajectory," Phillips said in a statement. "We will be rolling out several additional differentiated technologies and enhancements to our current portfolio over the coming weeks and months."

The FDA's 510(k) pathway allows manufacturers to market medical devices by demonstrating that they are substantially equivalent to legally marketed devices already available in the United States.